(Q30428632)
Statements
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC (English)
Ying Zhang
Fadila Guessous
Alex Kofman
David Schiff
Roger Abounader
1 February 2010
1 reference
1 reference
1 reference